



WELCOME

JPEO-CBD Medical Virtual Industry Day

<https://connect.dco.dod.mil/jpeocbdvid>

15 November 2012



UNCLASSIFIED



Joint Program Executive Office for Chemical and Biological Defense Medical Virtual Industry Day

Joint Program Executive Office for Chemical and Biological Defense

Joint Project Manager Transformational Medical Technologies (TMT) Overview

Mr. David Hough
Joint Project Manager
Transformational Medical Technologies
703.704.2374

November 15, 2012



Distribution Statement A: Approved for public release; distribution is unlimited.



Disclaimer



- **While we are presenting our currently planned business opportunities, we recognize that these may change given our changing fiscal environment and the strategic guidance of the Department of the Defense.**
- **New starts and increases to production levels in FY13 will be delayed until the Appropriations Bill is passed.**



JPM-TMT Organizational Structure



MR DAVID HOUGH
Joint Project Manager, TMT



JOHN GORRELL
Deputy JPM-TMT



LTC DAVID GIBSON
EID



DAVID KLAASSE
HFV



JPM-TMT Mission



MISSION:

Provide the Warfighter and the Nation with innovative medical solutions to protect against and treat emerging, genetically engineered, or unknown biothreats



Biological Defense Medical Products



JOINT PROJECT MANAGER TRANSFORMATIONAL MEDICAL TECHNOLOGIES

Protecting the Warfighter and the Nation from Biothreats

*Advanced Development and
Acquisition Programs*



*Hemorrhagic Fever Virus Class
Medical Countermeasures*



*Emerging Infectious Diseases-Influenza
Medical Countermeasure*

Capabilities



Animal Models & Enabling Technologies



Response Systems



Supporting Science & Technology Efforts

SCIENCE & TECHNOLOGY

ADVANCED DEVELOPMENT

Development of additional broad-spectrum MCM against naturally occurring and/or engineered EID threats

1

Development of new therapeutic animal model systems for Emerging Diseases

2

Manufacturing Scale Up of phosphorodiamidate morpholino (PMO) based MCMs

3

Development of Animal Models for an Aerosol route of exposure label indication

4

Reformulation of nucleotide based therapeutics for non-IV delivery

5

Development of new therapeutic animal model systems for Hemorrhagic Fever Viruses

6

Development of systems for early detection of virus in blood of animal models of infection

7

MCM Development Against Emerging Infectious Diseases

MCM Development Against Hemorrhagic Fever Viruses



Interagency & International Partners





Business Opportunities



1. HFV Class

- FY 14/15 – Backfill pipeline with candidates for advanced development
- Target all HFV Class beyond HFV *Filovirus* family
- Potential other HFV family targets include *Arenavirus* and *Bunyavirus*

2. Emerging Infectious Diseases

- FY14/15 – Evaluate spectrum of therapeutic response of current influenza drug candidate, *Favipiravir* (T-705) to diseases other than influenza
- Potential future programs include new therapeutic model systems for other Emerging Diseases

3. Animal Models

- Collaborate with FDA to qualify animal models that simulate human disease progression in laboratory animals
- Need for small animal and non-human primate models for diseases caused by *Arenavirus*, *Bunyavirus*, or *Filovirus*
- Capability to generate animal model data including facilities to handle animals and pathogens



JPM-TMT Funding Profile FY13-17 (Based on FY13 President's Budget)



Adv Dev \$K	FY13	FY14	FY15	FY16	FY17	TOTAL
TOTAL	\$79,127	\$129,775	\$112,571	\$89,669	\$86,761	\$497,903



JPM-TMT Points of Contact



Learn how we partner with industry, other government agencies and academia
www.jpmtmt.mil

FOLLOW US ON



@JPMTMT AND LIKE US ON



Use your smartphone to scan our QR code and go directly to our website.

